Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by gudisgoodon Aug 16, 2024 6:23am
106 Views
Post# 36182001

RE:RE:Q2/24 Comments

RE:RE:Q2/24 CommentsNot really. And regarding the overall GM-% in the future, well, for instance, it's really difficult to say how big of a share of the sales the BGx are going to have and whether we get further MOH contracts.

The GM-% is not the most important detail (although obviously, everything else being equal, we'd rather have a higher GM-% than a lower one). But obviously we'd prefer to have more MOH contracts (even though they seem to have somewhat lower GM-%) than not to have them.

The most important development is to see the absolute gross margin increase and, simultaneously, see the OPEX-% decrease. This should happen as we continue to onload new products to the platform while taking an advantage of the base that's already been built.

<< Previous
Bullboard Posts
Next >>